Lv3
300 积分 2022-03-18 加入
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
8小时前
已完结
Liquid Chromatography Combined With Tandem Mass Spectrometry for the Pharmacokinetic and Metabolism Studies of PROTAC ARV‐471 in Rats
8小时前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
8小时前
已完结
Vepdegestrant for the treatment of HR+/HER2– breast cancer
8小时前
已完结
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
8小时前
已完结
MA07.06 Eradicating Drug Tolerant Persisters (DTPs) In EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) By Targeting TROP2
1个月前
已关闭
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
1个月前
已完结
Site-Specific Binding of Anticancer Drugs to Human Serum Albumin
2个月前
已完结
Use of Albumin for Drug Delivery as a Diagnostic and Therapeutic Tool
2个月前
已完结
Supramolecular prodrug of SN38 based on endogenous albumin and SN38 prodrug modified with semaglutide side chain to improve the tumor distribution
2个月前
已完结
皖公网安备34019202002308
